Vincristine Sulfate

Type: Keyphrase

Name: Vincristine Sulfate

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Talon Therapeutics, Inc. Reports First Quarter 2013 Financial Results

(GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCQB:TLON), today reported financial results for the three months ended March 31, 2013.Corporate Highlights: Three Months EndedÂ March 31, 2013Â Unaudited Financial ResultsFor the three months endedÂ March ... [Published Nasdaq - May 15 2013]

Entities: Marqibo, Vincristine Sulfate, Acute Lymphoblastic Leukemia, Talon Therapeutics Inc, hepatic

First reported May 12 2013 - Updated May 12 2013 - 1 reports

Antibacterial, antidiarrhoeal, and cytotoxic activities of methanol extract and its fractions of ...

Caesalpinia bonducella is an important medicinal plant for its traditional uses against different types of diseases. Therefore, the present study investigated the antimicrobial, antidiarrhoeal, and cytotoxic activities of the methanol extract and ethyl ... [Published 7thSpace - May 12 2013]

Entities: fractionation, ethyl acetate, cytotoxic, Bactericide

First reported Apr 12 2013 - Updated Apr 12 2013 - 1 reports

Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) FDA Approval Call - Talon Therapeutics, Inc., - Earnings Transcript

Friday, August 10, 2012 04:00Corrected Transcripts are verbatim transcripts that have been reviewed and corrected by industry-focused financial professionals. Our editors re-listen to the entire call audio and confirm and research all the terms and numbers ... [Published Research and Markets - Apr 12 2013]

Entities: Marqibo, Vincristine Sulfate, Talon Therapeutics Inc, Liposome

First reported Apr 01 2013 - Updated Apr 01 2013 - 1 reports

Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2012 Financial Results

Unaudited Financial ResultsFor the three months ended December 31, 2012, the Company reported net income of $7.1 million and deemed dividends on preferred stock of $3.2 million, which when combined, resulted in net income applicable to common stockholders ... [Published Stockwatch - Apr 01 2013]

Entities: Marqibo, Vincristine Sulfate, Acute Lymphoblastic Leukemia, Talon Therapeutics Inc

First reported Jan 16 2013 - Updated Jan 16 2013 - 1 reports

MARQIBO (Vincristine Sulfate) Kit [Talon Therapeutics, Inc]

Updated Date: Jan 14, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Jan 16 2013]

Entities: Vincristine Sulfate, Marqibo, Talon Therapeutics Inc

First reported Jan 14 2013 - Updated Jan 15 2013 - 2 reports

MARQIBO (Vincristine Sulfate) Kit [Talon Therapeutics, Inc]

Updated Date: Jan 14, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Jan 15 2013]

Entities: Vincristine Sulfate, Marqibo, Talon Therapeutics Inc

Quotes

"We are actively working to grow the number of collaborators using our technology, including pharmaceutical, biotechnology and agricultural companies. We also anticipate some near-term milestones from existing partners, including Alnylam, which has guided that it will present initial data from its ALN-TTR02 Phase IIPhase II trial in mid-2013 and is on track to start a Phase III pivotal trial for ALN-TTR02 by the end of 2013. Tekmira expects to receive $10 million in milestone payments from Alnylam in 2013" stated Dr. Murray

Tekmira Provides Corporate Update and Announces First Quarter 2013 Results [Published Morningstar.com - May 14 2013]

"Examples of 'antimetabolites' include mercaptopurine, 6-mercaptopurine riboside, thioinosine, methotrexate, enocitabine, cytarabine, cytarabine ocfosfate, ancitabine hydrochloride, 5-FU drugs (e g., fluorouracil, tegafur, UFT, doxifluridine, carmofur, gallocitabine, emmitefur), aminopterine, leucovorin calcium, tabloid, butocine, folinate calcium, levofolinate calcium, cladribine, emitefur, fludarabine, gemcitabine, hydroxycarbamide, pentostatin, piritrexim, idoxuridine, mitoguazone, thiazophrine, and ambamustine, etc."

"Compositions of Botanical Extracts for Cancer Therapy" in Patent Application Approval Process [Published Pharmacy Choice - May 09 2013]

More Content

sort by: Date \| Relevance
Talon Therapeutics, Inc. Reports First Quarter ... [Published Nasdaq - May 15 2013]
Tekmira Provides Corporate Update and Announces... [Published Morningstar.com - May 14 2013]
Tekmira Pharmaceuticals loses $2.6-million in Q... [Published Stockwatch - May 14 2013]
Antibacterial, antidiarrhoeal, and cytotoxic ac... [Published 7thSpace - May 12 2013]
"Compositions of Botanical Extracts for Cancer ... [Published Pharmacy Choice - May 09 2013]
Targeting CD20: Rituximabâs Success Fuels Inter... [Published OncLive - Apr 25 2013]
Marqibo(R) (vinCRIStine sulfate LIPOSOME inject... [Published Research and Markets - Apr 12 2013]
Talon Therapeutics, Inc. Reports Fourth Quarter... [Published Stockwatch - Apr 01 2013]
A Big Year for Novel Drugs Approvals [Published I Am Biotech - Jan 17 2013]
MARQIBO (Vincristine Sulfate) Kit [Talon Therap... [Published DailyMed Drug Label Updates for the last seven ... - Jan 16 2013]
MARQIBO (Vincristine Sulfate) Kit [Talon Therap... [Published DailyMed Drug Label Updates for the last seven ... - Jan 15 2013]
MARQIBO (Vincristine Sulfate) Kit [Talon Therap... [Published DailyMed Drug Label Updates for the last seven ... - Jan 14 2013]
Talon Therapeutics, Inc. Reports Third Quarter ... [Published GlobeNewswire - Nov 14 2012]
Interferon-antibody fusion proteins demonstrati... [Published PharmCast - Sep 19 2012]
US FDA approves Talon Therapeutics' Marqibo [Published PharmaBiz - Aug 11 2012]
FDA Greenlights Agent for Rare Leukemia [Published BioPortfolio - Aug 10 2012]